FGFR2 and urothelial carcinoma: Pemigatinib is approved for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement,167 and relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.168 Erdafitinib is approved for patients with locally advanced or metastatic previously treated urothelial carcinoma positive for susceptible FGFR2 and FGFR3 genetic alterations, including certain fusions.169